Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Asian Stock Markets Start New Year Higher as Tech and AI Shares Drive Gains 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion 
Asian Markets Slip as Precious Metals Cool, Geopolitical Tensions Weigh on Sentiment 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
U.S. Dollar Starts 2026 Weak as Yen, Euro and Sterling Hold Firm Amid Rate Cut Expectations 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
